Midwest cooperative group evaluation of piposulfan (A-20968) in cancer.
D000230:Adenocarcinoma / Q000188:drug therapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use* / Q000633:toxicity; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D004064:Digestive System / Q000187:drug effects; D005260:Female; D006413:Hematopoietic System / Q000187:drug effects; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007938:Leukemia / Q000188:drug therapy; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D010954:Plasmacytoma / Q000188:drug therapy; D011087:Polycythemia Vera / Q000188:drug therapy; D012509:Sarcoma / Q000188:drug therapy
D000970:Antineoplastic Agents; D010879:Piperazines